相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。
Article
Cell Biology
Yueh-Ming Loo et al.
Summary: AZD7442, a combination of two monoclonal antibodies, has the potential to prevent and treat COVID-19 by neutralizing the SARS-CoV-2 virus. It has shown encouraging results in preventing infection and accelerating virus clearance in animal models. The ongoing phase 1 study has also demonstrated its ability to provide long-lasting protection in healthy participants. This research is significant in providing additional options for COVID-19 prevention and treatment.
SCIENCE TRANSLATIONAL MEDICINE
(2022)
Review
Oncology
Gianfranco Ferraccioli et al.
Summary: Vaccination has been crucial in combating the COVID-19 pandemic, but the emergence of immune-evading variants may prolong the clinical crisis. Understanding the molecular basis of different clinical stages and tailoring therapeutic approaches based on immune contexture is essential in limiting inflammation burden.
CANCER IMMUNOLOGY RESEARCH
(2022)
Article
Medicine, General & Internal
D. J. Sullivan et al.
Summary: This study evaluated the efficacy and safety of COVID-19 convalescent plasma in symptomatic adults and found that receiving convalescent plasma transfusion reduced the risk of hospitalization due to COVID-19-related reasons.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Medicine, General & Internal
Myron J. Levin et al.
Summary: A single dose of AZD7442 showed efficacy in preventing Covid-19 without evident safety concerns. The study suggests that AZD7442 may provide potential protection for individuals who have an inadequate response to vaccination or an increased risk of exposure.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Microbiology
Daniele Focosi et al.
Summary: The clinical use of anti-Spike monoclonal antibodies for COVID-19 therapy is threatened by the emergence of resistant lineages, which reduce their effectiveness. It is important to regularly assess the appropriateness and risk-benefit balance of these drugs.
Article
Medicine, General & Internal
R. Libster et al.
Summary: A randomized, double-blind, placebo-controlled trial of convalescent plasma with high IgG titers against SARS-CoV-2 in older adult patients within 72 hours after the onset of mild Covid-19 symptoms found that early administration of high-titer convalescent plasma reduced the progression of Covid-19 in mildly ill infected older adults.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Review
Pharmacology & Pharmacy
Carlos Cruz-Teran et al.
Summary: The article discusses the global efforts to combat the COVID-19 pandemic with potent neutralizing mAbs and highlights the challenges faced by current antiviral mAbs. It also presents evidence supporting inhaled delivery of antiviral mAbs as an early intervention against COVID-19.
ADVANCED DRUG DELIVERY REVIEWS
(2021)
Review
Immunology
Vincent Dussupt et al.
Summary: The unprecedented Zika outbreak in the Americas from 2015-2016 led to global concern and accelerated the deployment of vaccine and therapeutic countermeasures. Several potent neutralizing antibodies against Zika and related flaviviruses have been discovered in recent years. Structure-based approaches have helped identify species-specific and cross-protective epitopes with therapeutic value.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Medicine, General & Internal
Myron S. Cohen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2021)
Article
Medicine, General & Internal
M. P. O'Brien et al.
Summary: The study indicates that subcutaneous REGEN-COV can effectively prevent severe Covid-19 and reduce the duration of symptoms in individuals at high risk for infection due to household exposure to confirmed SARS-CoV-2 cases.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Review
Biotechnology & Applied Microbiology
Saeid Najafi Fard et al.
Summary: Coronaviruses are enveloped nonsegmented positive-sense RNA viruses with the largest genome among RNA viruses. The Spike (S) protein is crucial in viral tropism, mediating viral attachment and cell entry. In vitro models have been developed to study CoVs entry and pathogenesis, and inhibiting the binding of the S protein to cell receptors may offer therapeutic opportunities.
BIOMED RESEARCH INTERNATIONAL
(2021)
Review
Medicine, General & Internal
Massimo Franchini et al.
Summary: This study aimed to summarize evidence on the efficacy and safety of convalescent plasma (CP) in treating COVID-19. Results showed a reduction in mortality with CP over standard therapy when administered early and at high titer, without increased adverse reactions, although there was variability in the certainty of the evidence.
Article
Immunology
Rosa Rodriguez-Fernandez et al.
Summary: RSV is a major cause of hospitalizations in infants, and Palivizumab is the only licensed agent for preventing severe RSV infection in high-risk infants. New generation mAbs targeting neutralizing epitopes are expected to provide better protection with fewer injections.
PEDIATRIC INFECTIOUS DISEASE JOURNAL
(2021)
Article
Immunology
Rosa Rodriguez-Fernandez et al.
Summary: RSV is the leading cause of hospitalizations in infants globally, and Palivizumab is currently the only approved drug for preventing severe RSV infection in high-risk infants. Advances in monoclonal antibody technology have paved the way for the development of new strategies for preventing RSV infections, with a focus on new neutralizing epitopes and improved half life of antibodies.
PEDIATRIC INFECTIOUS DISEASE JOURNAL
(2021)
Review
Immunology
Peter C. Taylor et al.
Summary: The study discusses the clinical utility of neutralizing monoclonal antibody therapies targeting SARS-CoV-2, emphasizing the importance of patient stratification, biomarkers, risk factors, and other clinical considerations.
NATURE REVIEWS IMMUNOLOGY
(2021)
Review
Cell Biology
Ruei-Min Lu et al.
JOURNAL OF BIOMEDICAL SCIENCE
(2020)
Editorial Material
Medicine, General & Internal
Myron M. Levine
NEW ENGLAND JOURNAL OF MEDICINE
(2019)
Article
Infectious Diseases
Mark H. Wilcox et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2017)
